Javier Trigo-López1, Ángel Luis Guerrero-Peral2,3,4, Álvaro Sierra1, Enrique Martínez-Pías1, María Gutiérrez-Sánchez1, Elizabeth Huzzey5,6, David García-Azorín1. 1. Headache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Avenida Ramón y Cajal 3, 47005, Valladolid, Spain. 2. Headache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Avenida Ramón y Cajal 3, 47005, Valladolid, Spain. gueneurol@gmail.com. 3. Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. gueneurol@gmail.com. 4. Department of Medicine, University of Valladolid, Valladolid, Spain. gueneurol@gmail.com. 5. OPHM, London, UK. 6. University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: We aim to describe and compare patients and general practitioners' opinions about the different variables related to acute and preventive treatment for migraine. PATIENTS AND METHODS: An observational descriptive study was performed. Patients with episodic migraine and general practitioners, from our healthcare area, were invited to answer a survey about the different variables related to migraine treatment. They were asked for their opinions on the different variables, and to consider the desired efficacy in percentage terms and the desired action times of treatment. RESULTS: Fifty-five patients and fifty-five general practitioners were selected. Effectiveness was considered the most important variable for symptomatic and preventive treatment. Cost was considered the least important variable. Patients desired percentage of efficacy was 84.0% (±16.7%) for symptomatic treatment and 79.9% (±17.1%) for preventive treatment. General practitioners desired percentage of efficacy was 75.0% (±14.0) for symptomatic treatment and 70.4% (±14.3) for preventive treatment. For symptomatic treatment the desired action time for pain cessation was selected as 27.5 min (±13.8) for patients and 24.0 min (±18.3) for GPs. For preventive treatment the desired action time for effect was 7.1 days (±4.5) for patients and 13.9 days (±8.9) for general practitioners. CONCLUSION: The most important endpoints were, for acute: effectiveness, a short action time and a persistent effect. For prophylactic: effectiveness, sustained effect and tolerability. Both patients and general practitioners agreed on the most and least preferred endpoints. Desired percentage of efficacy was above 75% for both symptomatic and preventive treatment; and the desired action time was below 30 min for acute treatment and 2 weeks for preventive treatment.
BACKGROUND: We aim to describe and compare patients and general practitioners' opinions about the different variables related to acute and preventive treatment for migraine. PATIENTS AND METHODS: An observational descriptive study was performed. Patients with episodic migraine and general practitioners, from our healthcare area, were invited to answer a survey about the different variables related to migraine treatment. They were asked for their opinions on the different variables, and to consider the desired efficacy in percentage terms and the desired action times of treatment. RESULTS: Fifty-five patients and fifty-five general practitioners were selected. Effectiveness was considered the most important variable for symptomatic and preventive treatment. Cost was considered the least important variable. Patients desired percentage of efficacy was 84.0% (±16.7%) for symptomatic treatment and 79.9% (±17.1%) for preventive treatment. General practitioners desired percentage of efficacy was 75.0% (±14.0) for symptomatic treatment and 70.4% (±14.3) for preventive treatment. For symptomatic treatment the desired action time for pain cessation was selected as 27.5 min (±13.8) for patients and 24.0 min (±18.3) for GPs. For preventive treatment the desired action time for effect was 7.1 days (±4.5) for patients and 13.9 days (±8.9) for general practitioners. CONCLUSION: The most important endpoints were, for acute: effectiveness, a short action time and a persistent effect. For prophylactic: effectiveness, sustained effect and tolerability. Both patients and general practitioners agreed on the most and least preferred endpoints. Desired percentage of efficacy was above 75% for both symptomatic and preventive treatment; and the desired action time was below 30 min for acute treatment and 2 weeks for preventive treatment.
Authors: Matthew J Khayata; Samantha Farley; J Kelly Davis; Christoph P Hornik; Bryce B Reeve; Aruna Rikhi; Amy A Gelfand; Christina L Szperka; Shirley Kessel; Tara Pezzuto; Alex Hammett; Monica E Lemmon Journal: Headache Date: 2022-05-06 Impact factor: 5.311